https://www.nuancepharma.com//about/about-us 1.0 2026-03-12 weekly https://www.nuancepharma.com//about/about-us 1.0 2026-03-12 weekly https://www.nuancepharma.com//about/leadership 1.0 2026-03-12 weekly https://www.nuancepharma.com//about/leadership?tp=2 1.0 2026-03-12 weekly https://www.nuancepharma.com//about/milestones 1.0 2026-03-12 weekly https://www.nuancepharma.com//product/product-all 1.0 2026-03-12 weekly https://www.nuancepharma.com//product/product-all 1.0 2026-03-12 weekly https://www.nuancepharma.com//product/iron-deficiency-anemia 1.0 2026-03-12 weekly https://www.nuancepharma.com//product/emergency-care 1.0 2026-03-12 weekly https://www.nuancepharma.com//product/respiratory-1 1.0 2026-03-12 weekly https://www.nuancepharma.com//pipeline 1.0 2026-03-12 weekly https://www.nuancepharma.com//pipeline?tp=1 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly https://www.nuancepharma.com//partnership 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/news-all 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/news-all 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/25.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/29.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/37.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/40.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/67.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/68.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/75.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/76.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/press-releases/77.html 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/media-reports 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-closes-series-d-financing-301841.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/global/verona-pharma-and-nuance-pharma-announce-219-million-strategic-collaboration-to-develop-and-commercialize-ensifentrine-in-greater-china-321877.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/global/aerogen-pharma-enters-into-exclusive-agreements-with-nuance-pharma-to-advance-treatment-of-respiratory-distress-syndrome-in-premature-infants-in-china-346472.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/global/nuance-pharma-acquires-sino-health-to-further-strengthen-its-commercial-capabilities-and-expand-pipelines-347675.shtml 1.0 2026-03-12 weekly https://www.accesswire.com/691580/Altamira-Therapeutics-and-Nuance-Pharma-Enter-Into-Exclusive-Licensing-and-Distribution-Agreement-for-Bentrio-in-China-and-Additional-Asian-Markets 1.0 2026-03-12 weekly https://en.prnasia.com/releases/global/nuance-pharma-announces-the-completion-of-dosing-for-all-ntm-001-phase-1-clinical-study-participants-in-hku-clinical-trials-centre-369621.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-announces-partnership-with-dksh-to-launch-bentrio-nasal-spray-in-hong-kong-and-macau-385306.shtml 1.0 2026-03-12 weekly https://www.prnewswire.com/news-releases/nuance-pharma-announces-clearance-of-ind-application-for-ensifentrine-pivotal-clinical-trials-for-copd-in-china-301609010.html 1.0 2026-03-12 weekly https://www.vbdata.cn/1518879011 1.0 2026-03-12 weekly https://www.prnewswire.com/news-releases/nuance-pharma-announces-dosing-of-first-patient-in-enhance---china-phase-iii-trial-for-chronic-obstructive-pulmonary-disease-copd-301791655.html 1.0 2026-03-12 weekly https://www.vbdata.cn/ZTFhOTBmYzk5NTlhZDc2YmM3MWFiMWRhMjIwZDY4ODY= 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-s-partner-verona-pharma-submits-new-drug-application-to-us-fda-for-ensifentrine-for-the-maintenance-treatment-of-copd-409638.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/altamira-therapeutics-reports-positive-top-line-data-from-bentrio-clinical-trial-in-seasonal-allergic-rhinitis-405418.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/us-fda-new-drug-application-approval-of-ohtuvayre-ensifentrine-for-the-maintenance-treatment-of-copd-452286.shtml 1.0 2026-03-12 weekly https://pharmaboardroom.com/interviews/mark-lotter-founder-ceo-nuance-pharma/ 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of-ensifentrine-for-the-maintenance-treatment-of-copd-460333.shtml 1.0 2026-03-12 weekly https://en.prnasia.com/story/archive/4512694_AE12694_0?utm_source=cleartime-customer&utm_medium=email 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-announces-approval-of-ohtuvayre-ensifentrine-in-macau-sar-china-477835.shtml 1.0 2026-03-12 weekly https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ensifentrine-meets-primary-endpoint-in-phase-3-enhance-china-trial-for-copd-302457563.html 1.0 2026-03-12 weekly https://en.prnasia.com/releases/apac/nuance-pharma-announces-acceptance-for-review-of-the-new-drug-application-for-ohtuvayre-ensifentrine-by-the-national-medical-products-administration-of-china-for-the-maintenance-treatment-of-chronic-obstructive-pulmonary-disease-520315.shtml 1.0 2026-03-12 weekly https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-approval-of-ohtuvayre-ensifentrine-in-hong-kong-sar-china-302712086.html?tc=eml_cleartime 1.0 2026-03-12 weekly https://www.nuancepharma.com//news/partner-news 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-completes-enrollment-in-phase-3-enhance-1-trial-evaluating-ensifentrine-for-maintenance-treatment-of-copd/ 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-announces-ensifentrine-meets-primary-endpoint-in-phase-3-enhance-2-trial-for-copd/ 1.0 2026-03-12 weekly https://neumentum.com/neumentum-and-nuance-biotech-enter-into-licensing-agreement-for-ntm-001-ketorolac-for-iv-infusion-in-china/ 1.0 2026-03-12 weekly https://feeds.issuerdirect.com/news-release.html?newsid=7697067252927652 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-announces-analyses-demonstrating-ensifentrine-reduced-exacerbation-rates-across-subgroups-in-phase-3-enhance-2-trial-for-copd/ 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-announces-ensifentrine-meets-primary-and-key-secondary-endpoints-in-phase-3-enhance-1-trial-for-copd/ 1.0 2026-03-12 weekly https://feeds.issuerdirect.com/news-release.html?newsid=8602572652590653 1.0 2026-03-12 weekly https://www.accesswire.com/741841/Clinical-Study-Demonstrates-Bentrios-Superior-Nasal-Residence-Time-and-Rheological-Properties 1.0 2026-03-12 weekly https://www.accesswire.com/viewarticle.aspx?&id=739164 1.0 2026-03-12 weekly https://www.accesswire.com/756785/Altamira-Therapeutics-Reports-Positive-Top-Line-Data-from-Bentrio-Clinical-Trial-in-Seasonal-Allergic-Rhinitis 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-submits-new-drug-application-to-us-fda-for-ensifentrine-for-the-maintenance-treatment-of-copd/ 1.0 2026-03-12 weekly https://www.veronapharma.com/news/nuance-pharma-announces-dosing-of-first-patient-in-enhance-china-phase-3-trial-for-copd/ 1.0 2026-03-12 weekly https://www.veronapharma.com/news/verona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine/ 1.0 2026-03-12 weekly https://ir.altamiratherapeutics.com/news-releases/news-release-details/altamira-therapeutics-announces-expansion-bentrio-license-and 1.0 2026-03-12 weekly https://feeds.issuerdirect.com/news-release.html?newsid=4850392352390955&symbol=CYTO,CYTOF 1.0 2026-03-12 weekly https://www.nuancepharma.com//investors 1.0 2026-03-12 weekly https://www.nuancepharma.com//careers 1.0 2026-03-12 weekly https://www.nuancepharma.com//careers?tp=1 1.0 2026-03-12 weekly https://www.nuancepharma.com//careers?tp=2 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly 1.0 2026-03-12 weekly https://www.nuancepharma.com//contact 1.0 2026-03-12 weekly https://www.nuancepharma.com//Ch/Index/aeReport 1.0 2026-03-12 weekly